Shares
Acasti’s shares plunge as new drug does not meet primary endpoint
January 14, 2020Manufacturing and Production Acasti, Acasti Pharma, CaPre, Primary Endpoint, Shares
Acasti Pharma’s shares plunged by as much as 67% this week as its drug CaPre failed to meet its primary …
Novartis exec sold off shares before Zolgensma data scandal was revealed
August 19, 2019Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market
An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …
Novo Holdings invests £53.5 million into Oxford Biomedica
May 30, 2019Business Services, Sales and Marketing Novo Holdings, Novo Nordisk, Oxford BioMedica, Shares, cell and gene therapy, lentivirus
Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million. Novo will buy …
ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial
May 16, 2019Business Services, Research and Development Cancer, Immunogen, Shares, ovarian cancer, pharma, stocks
Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 …
Gilead shares drop 4% after failure of NASH drug to meet primary endpoint
February 12, 2019Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib
Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …
J&J announces $5bn share repurchase
December 18, 2018Manufacturing and Production J&J, JJ, Shares, asbestos, baby powder, reuters, scandal
New Jersey-based pharma firm Johnson & Johnson plans to buy back $5 billion in shares after news agency Reuters released …
Samsung Biologics shares fall by 20% after Korean investigation
November 13, 2018Manufacturing and Production Shares, accounting, pharma, smasung biologics, stockmarket
Shares in Korean firm Samsung BioLogics plummeted this week, falling by as much as 20% on Monday, after the South …
Pharma stocks soar after US midterm elections
November 8, 2018Business Services, Manufacturing and Production Shares, Stock, Trump, biotech, pharma, stock market
Despite the threat of a bipartisan pricing plan, pharma stocks have soared after the announcement of the results of the …
Shares in Molecular Templates surge after the announcement of Takeda collaboration
September 20, 2018Business Services, Research and Development Molecular Templates, Shares, Takeda, markets, stocks
Shares in the Texas based biotech Molecular Templates have soared after the company announced that they would be collaborating with …
Realm Therapeutics shares halved after failure of Phase 2 study
August 15, 2018Research and Development London, Shares, atopic dermatitis, phase 2, stock market
Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the …
Regeneron Pharma and Bluebird bio announce immune cell collaboration
August 6, 2018Sales and Marketing Cancer, Regeneron, Shares, bluebird, collaboration, t cells, t-cells
Regeneron Pharmaceuticals have announced that they will collaborate with the Massachusetts-based gene therapy specialist Bluebird bio in an effort to …
Alnylam’s shares plunge by 42% after deaths in clinical trials
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran
Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…
July 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics
Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …
Weekly Movers: Regulus, Nymox, Akers…
July 4, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks
Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food …
Immunomedics’ chief financial officer resigns, shares fall
June 22, 2016Research and Development, Sales and Marketing Immunomedics, Shares, cfo, stock market
Shares in Immunomedics (Nasdaq: IMMU) fell as much as 11% after the company said its chief financial officer Peter Pfreundschuh …
